Short-Term Ex Vivo Culture of CTCs from Advance Breast Cancer Patients: Clinical Implications DOI Open Access
Nuria Carmona-Ule,

Miriam González-Conde,

Carmen Abuín

et al.

Cancers, Journal Year: 2021, Volume and Issue: 13(11), P. 2668 - 2668

Published: May 28, 2021

Background: Circulating tumor cells (CTC) have relevance as prognostic markers in breast cancer. However, the functional properties of CTCs or their molecular characterization not been well-studied. Experimental models indicate that only a few can survive circulation and eventually metastasize. Thus, it is essential to identify these surviving capable forming such metastases. Methods: We isolated viable from 50 peripheral blood samples obtained 35 patients with advanced metastatic cancer using RosetteSepTM for ex vivo culture. The were seeded monitored on plates under low adherence conditions media supplemented growth factors Nanoemulsions. Phenotypic analysis was performed by immunofluorescence gene expression RT-PCR counting Cellsearch® system. Results: found 75% CTC cultures lasted more than 23 days, predicting shorter Progression-Free Survival patients, independently having ≥5 Cellsearch®. also observed before after culture showed different profile. Conclusions: cultivability predictive factor. Furthermore, subset growing show stem mesenchymal features may represent population potential vivo.

Language: Английский

Liquid Biopsy: From Discovery to Clinical Application DOI Open Access
Catherine Alix‐Panabières, Klaus Pantel

Cancer Discovery, Journal Year: 2021, Volume and Issue: 11(4), P. 858 - 873

Published: April 1, 2021

Over the past 10 years, circulating tumor cells (CTC) and DNA (ctDNA) have received enormous attention as new biomarkers subjects of translational research. Although both are already used in numerous clinical trials, their utility is still under investigation with promising first results. Clinical applications include early cancer detection, improved staging, detection relapse, real-time monitoring therapeutic efficacy, targets resistance mechanisms. Here, we propose a conceptual framework CTC ctDNA assays point out current challenges research, which might structure this dynamic field SIGNIFICANCE: The analysis blood for CTCs or cell-free nucleic acids called "liquid biopsy" has opened avenues diagnostics, including tumors, risk assessment well relapse evolution context therapies.

Language: Английский

Citations

392
Circulating tumour cells for early detection of clinically relevant cancer DOI Open Access
Rachel Lawrence,

Melissa Watters,

Caitlin R. Davies

et al.

Nature Reviews Clinical Oncology, Journal Year: 2023, Volume and Issue: 20(7), P. 487 - 500

Published: June 2, 2023

Language: Английский

Citations

181
Novel approaches to target the microenvironment of bone metastasis DOI
Lorenz C. Hofbauer, Aline Bözec, Martina Rauner

et al.

Nature Reviews Clinical Oncology, Journal Year: 2021, Volume and Issue: 18(8), P. 488 - 505

Published: April 19, 2021

Language: Английский

Citations

145
The potential of liquid biopsy in the management of cancer patients DOI
Athina Markou,

Eleni Tzanikou,

Evi Lianidou

et al.

Seminars in Cancer Biology, Journal Year: 2022, Volume and Issue: 84, P. 69 - 79

Published: March 21, 2022

Language: Английский

Citations

96
Multi-stage mechanisms of tumor metastasis and therapeutic strategies DOI Creative Commons
Zaoqu Liu, Jingqi Chen, Yuqing Ren

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Oct. 11, 2024

The cascade of metastasis in tumor cells, exhibiting organ-specific tendencies, may occur at numerous phases the disease and progress under intense evolutionary pressures. Organ-specific relies on formation pre-metastatic niche (PMN), with diverse cell types complex interactions contributing to this concept, adding a new dimension traditional cascade. Prior metastatic dissemination, as orchestrators PMN formation, primary tumor-derived extracellular vesicles prepare fertile microenvironment for settlement colonization circulating cells distant secondary sites, significantly impacting cancer progression outcomes. Obviously, solely intervening sites passively after macrometastasis is often insufficient. Early prediction holistic, macro-level control represent future directions therapy. This review emphasizes dynamic intricate systematic alterations that progresses, illustrates immunological landscape creation, deepens understanding treatment modalities pertinent metastasis, thereby identifying some prognostic predictive biomarkers favorable early predict occurrence design appropriate combinations.

Language: Английский

Citations

27
Circulating tumor cells as liquid biopsy markers in cancer patients DOI Creative Commons
Daniel J. Smit, Klaus Pantel

Molecular Aspects of Medicine, Journal Year: 2024, Volume and Issue: 96, P. 101258 - 101258

Published: Feb. 21, 2024

Over the past decade, novel methods for enrichment and identification of cancer cells circulating in blood have been established. Blood-based detection other tumor-associated products can be summarized under term Liquid Biopsy. Circulating tumor (CTCs) used diagnosis, risk stratification treatment selection as well monitoring several studies over years, thus representing a valuable biomarker patients. A plethora to enrich, detect analyze CTCs has In contrast liquid biopsy analytes (e.g. ctDNA), represent viable analyte that provides unique opportunity understand underlaying biology metastatic cascade on molecular level. this review, we provide an overview current enrichment, detection, functional characterization CTCs.

Language: Английский

Citations

24
Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1–HER3 signaling DOI Creative Commons
Roberto Würth, Elisa Donato, Laura L. Michel

et al.

Nature Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 3, 2025

Abstract Circulating tumor cells (CTCs) drive metastasis, the leading cause of death in individuals with breast cancer. Due to their low abundance circulation, robust CTC expansion protocols are urgently needed effectively study disease progression and therapy responses. Here we present establishment long-term CTC-derived organoids from female metastatic Multiomics analysis along preclinical modeling xenografts identified neuregulin 1 (NRG1)–ERBB2 receptor tyrosine kinase 3 ( ERBB3 /HER3) signaling as a key pathway required for survival, growth dissemination. Genome-wide CRISPR activation screens revealed that fibroblast factor (FGFR1) serves compensatory function NRG1–HER3 axis rescues NRG1 deficiency CTCs. Conversely, induced resistance FGFR1 inhibition, whereas combinatorial blockade impaired growth. The dynamic interplay between reveals molecular basis cancer cell plasticity clinically relevant strategies target it. Our organoid platform enables identification validation patient-specific vulnerabilities represents an innovative tool precision medicine.

Language: Английский

Citations

4
Epithelial Cell Adhesion Molecule: An Anchor to Isolate Clinically Relevant Circulating Tumor Cells DOI Creative Commons
Zahra Eslami‐S, Luis Enrique Cortés‐Hernández, Catherine Alix‐Panabières

et al.

Cells, Journal Year: 2020, Volume and Issue: 9(8), P. 1836 - 1836

Published: Aug. 5, 2020

In the last few decades, epithelial cell adhesion molecule (EpCAM) has received increased attention as main membrane marker used in many enrichment technologies to isolate circulating tumor cells (CTCs). Although there been a great deal of progress implementation EpCAM-based CTC detection medical settings, several issues continue limit their clinical utility. The biology EpCAM and its role are not completely understood but evidence suggests that expression this cell-surface protein is crucial for metastasis-competent CTCs may be lost during epithelial-to-mesenchymal transition. review, we summarize most significant advantages disadvantages using potential biological metastatic cascade.

Language: Английский

Citations

109
Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors DOI Open Access
Pamela Pinzani, Valeria D’Argenio, Marzia Del Re

et al.

Clinical Chemistry and Laboratory Medicine (CCLM), Journal Year: 2021, Volume and Issue: 59(7), P. 1181 - 1200

Published: Feb. 5, 2021

Despite advances in screening and therapeutics cancer continues to be one of the major causes morbidity mortality worldwide. The molecular profile tumor is routinely assessed by surgical or bioptic samples, however, genotyping tissue has inherent limitations: it represents a single snapshot time subjected spatial selection bias owing heterogeneity. Liquid biopsy emerged as novel, non-invasive opportunity detecting monitoring several body fluids instead tissue. Circulating cells (CTCs), circulating DNA (ctDNA), RNA (mRNA microRNA), microvesicles, including exosomes "educated platelets" were recently identified source genomic information patients which could reflect all subclones present primary metastatic lesions allowing sequential disease evolution. In this review, we summarize currently available concerning liquid breast cancer, colon lung melanoma. These promising issues still need standardized harmonized across laboratories, before fully adopting approaches into clinical practice.

Language: Английский

Citations

93
Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels DOI Creative Commons
Stanley P. L. Leong, Kamila Naxerova, Laura Keller

et al.

Clinical & Experimental Metastasis, Journal Year: 2021, Volume and Issue: 39(1), P. 159 - 179

Published: Nov. 12, 2021

Cancer metastasis is the process by which primary cancer cells invade through lymphatic or blood vessels to distant sites. The molecular mechanisms spread either versus both are not well established. Two major developments have helped us understand more clearly. First, development of sentinel lymph node (SLN) concept established in melanoma and breast cancer. SLN first draining nodal basin receive cells. Patients with a negative biopsy show significantly lower incidence metastasis, suggesting that may be gateway for these types. Second, discovery characterization several biomarkers including VEGF-C, LYVE-1, Podoplanin Prox-1 opened new vistas understanding induction lymphangiogenesis must complete multiple steps system, some enabled evolution traits during progression. Thus, initially main SLN, from evolving clones can also enter directly, bypassing establish metastases. Future studies need pinpoint molecules used at different stages via routes so specific therapies targeted against molecules, goal stopping preventing metastasis.

Language: Английский

Citations

74